# Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-first-quarter-2026-financial-results
Ticker: ALGS
Company: Aligos Therapeutics
Source: Aligos Therapeutics
Published: 2026-05-07 20:06 EST
Original Source URL: https://investor.aligos.com
## Summary

SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and

## Article Body
SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and
## Recent Company News
- 2026-05-27 06:30 EST — [Aligos Therapeutics Presents Positive Data at the EASL Congress 2026](https://biopharmsignal.com/news/ALGS/aligos-therapeutics-presents-positive-data-at-the-easl-congress-2026) — Source: Aligos Therapeutics
- 2026-05-13 06:05 EST — [Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026](https://biopharmsignal.com/news/ALGS/aligos-therapeutics-announces-ten-abstracts-accepted-for-presentation-at-the-easl-congress-2026) — Source: Aligos Therapeutics
- 2026-05-07 20:06 EST — [Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results](https://biopharmsignal.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-first-quarter-2026-financial-results) — Source: Aligos Therapeutics
- 2026-04-30 20:05 EST — [Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026](https://biopharmsignal.com/news/ALGS/aligos-therapeutics-to-announce-1st-quarter-2026-financial-results-on-may-7-2026) — Source: Aligos Therapeutics
- 2026-04-24 12:00 EST — [Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ALGS/aligos-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Aligos Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)